
CytoAgents Completes Cohort 1 Dose-Escalation in Phase 1B Clinical Trial for Cytokine Release Syndrome Research
CytoAgents Completes Cohort 1 Dose-Escalation in Phase 1B Clinical Trial for Cytokine Release Syndrome Research CytoAgents Inc., a clinical-stage biotechnology company at the forefront of developing therapies for immune-mediated disorders, has announced a significant milestone in its ongoing Phase 1b/2a…